The biopharmaceutical industry is known as Taiwan’s next sacred mountain for protecting the country.  The government pays special attention to the policy on the industry’s development.  The 2021 amendment to the Act for the Development of Biotech and Pharmaceutical Industry offers a great opportunity for the contract development and manufacturing Company (CDMO) sector.

Regarding the biopharmaceutical industry’s development models, in addition to independent research and development, companies often seek new opportunities, enter new markets or raise capital through authorization, mergers and acquisitions.  However, there are different considerations for each model.  It is therefore essential for companies to clarify their operation and financial planning and take into account of their future directions in order to seize the best opportunity for development. 

Hence, PwC Legal and TPMA hosted a seminar on “Taiwan Biopharmaceutical Industry Licensing, Market Entry and Joint Venture and M&A Opportunities” in October 2022, inviting representatives from the academic, the industry and the government to discuss the latest issues concerning the biopharmaceutical industry. 

The Executive of PwC Taiwan said at the seminar that PwC Taiwan continues to pay attention to the growth in the Asia-Pacific region and to provide integrated services in this region, including consulting services on the new southbound investment, mergers, acquisitions, etc. with a view to facilitating the government’s new southbound policy and supporting clients in the post-pandemic era.

Su Dong-Mao, the President of TPMA, pointed out the amendment to the Act for the Development of Biotech and Pharmaceutical Industry helps to support the development of the biopharmaceutical industry in facing the challenges in the post-pandemic era.  Taiwan’s biopharmaceutical industry is ready to seize the opportunity.

Taiwan has a solid industry value chain involving R&D, manufacturing and sales.  Companies should grasp the opportunities for CDMOs brought about by the amendment to the Act for the Development of Biotech and Pharmaceutical Industry and build an Asia-Pacific biopharmaceutical CDMO ecosystem based on Taiwan’s advantages.

【2022-10-31 / Economic Daily】